SFR-1882

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameSFR-1882
Drug Alias NamerHSA-EPO (SinoBiotech/FortuneRock/Beijing Bio-Fortune/Tianjin Linda)SFR-1882
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterferon alpha 2 ligandErythropoietin receptor agonists
TargetsInterferon alpha-2Erythropoietin receptor
Therapy Area/IndicationsAnemiaRenal Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTianjin Sinobiotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Sinobiotech LtdBeijing Bio-Fortune LtdTianjin Linda Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsAnemiaRenal Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A